Prostate-specific membrane antigen (PSMA) as a theranostic agent is driving changes in prostate cancer including both clinical development of new drugs and clinical care. The sensitivity of PSMA imaging has created impatience in industry and the clinic alike to replace traditional computed tomography and bone scan in clinical practice and drug development. However, the success of PSMA as a therapeutic target might limit the ability of PSMA imaging to adequately define prostate cancer in a therapeutic landscape where highly effective PSMA-based therapies are used early in the disease course.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).
Pienta, K. J. et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J. Urol. 206, 52–61 (2021).
Morris, M. J. et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404, 1227–1239 (2024).
Sartor, A. O. et al. PSMA-delay castration (DC): an open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC). J. Clin. Oncol. 43 (Suppl. 16), TPS5127 (2025).
Mulati, Y. et al. Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases. Sci. Rep. 15, 23902 (2025).
Li, S. et al. Resistance to antibody-drug conjugates: a review. Acta Pharm. Sin. B 15, 737–756 (2025).
Loganzo, F. et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol. Cancer Ther. 14, 952–963 (2015).
Scaltriti, M. et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99, 628–638 (2007).
Chen, R. et al. Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma. Clin. Cancer Res. 26, 1034–1044 (2020).
Fitzpatrick, K. J. et al. 177Lu-PSMA-617 single-photon emission computed tomography/computed tomography dosimetry and radiobiological models demonstrate decreasing tumor-to-kidney dose ratio with successive cycles. Int. J. Radiat. Oncol. Biol. Phys. https://doi.org/10.1016/j.ijrobp.2025.06.3869 (2025).
Parghane, R. V. & Basu, S. PET/computed tomography in treatment response assessment in cancer: an overview with emphasis on the evolving role in response evaluation to immunotherapy and radiation therapy. PET Clin. 15, 101–123 (2020).
Fletcher, J. W. et al. Recommendations on the use of 18F-FDG PET in oncology. J. Nucl. Med. 49, 480–508 (2008).
Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 23, 1389–1397 (2022).
Borea, R. et al. Beyond the prognostic value of 2-[18F]FDG PET/CT in prostate cancer: a case series and literature review focusing on the diagnostic value and impact on patient management. Diagnostics 12, 581 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Abel, M.L., Sharp, A., Posadas, E.M. et al. Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging. Nat Rev Urol (2025). https://doi.org/10.1038/s41585-025-01100-z
Published:
DOI: https://doi.org/10.1038/s41585-025-01100-z
